The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook

References

• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131(5):1288-96
   PubMed Web of Science ®Google Scholar
• Calderon MA, Gerth van Wijk R, Eichler I, et al. Perspectives on allergen –specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012;23(4):300-6
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis. and eczema in childhood :ISAAC Phases One and Three repeat multicountry cross-sectional surveys. ISAAC Phase Three Study Group. Lancet 2006;368(9537):733-43
   PubMed Web of Science ®Google Scholar
• Muraro A, Werfel T, Hoffmann Sommergruber K, et al. EAACI Food. Allergy and Anaphylaxis Guidelines: diagnosis and management of food Allergy. 2014;69(8):1008-25
   Google Scholar
• Calderon MA, Demoly P, Gerth van Wijk R, et al. EAACI: a European Declaration on Immunotherapy. Designing the future of allergen Specific immunotherapy. Clin Trans. Allergy 2012;2(1):20
   Google Scholar
• Pajno GB. Oral desensitization for milk allergy in children: state of the art. Curr. Opin. Allergy Clin. Immunol 2011;11(6):560-4
   Web of Science ®Google Scholar
• Pajno GB, Cox L, Caminiti L. Ramistella V, Crisafulli G. Oral Immunotherapy for Treatment of Immunoglobulin E-Mediated Food Allergy: the Transition to Clinical Practice. Pediatr. Allergy Immunol. Pulmonol 2014;27(2):42-50
   Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;1:CD003559
   PubMed Web of Science ®Google Scholar
• Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 2011;127(6):1622-4
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Biologic agents in the treatment of urticaria. Curr Allergy Asthma Rep 2012;12(4):288-91
   PubMed Web of Science ®Google Scholar
• Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572
   Google Scholar
• Ogawa M, Kochwa S, Smith C, et al. Clinical aspects of IgE myeloma. N Engl J Med 1969;281(22):1217-20
   PubMed Web of Science ®Google Scholar
• Lowell FC, Franklin WA. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med. 1965;273(13):675-9
   Google Scholar
• Bukantz SC, Bagg AS, Lockey RF. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008;21:455-68
   PubMedGoogle Scholar
• Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008;8(6):571-6
   PubMed Web of Science ®Google Scholar
• Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists’ experiences and recommendations for prevention. J Allergy Clin Immunol 2004;113(6):1117-21
   PubMed Web of Science ®Google Scholar
• Committee on the safety of Medicine: desensitizing of vaccine. BMJ 1989;293:948
   Google Scholar
• Passalacqua G, Canonica GW. Local nasal specific immunotherapy for allergic rhinitis. Allergy Asthma Clin Immunol 2006;15:2(3):117-23
   Google Scholar
• Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111(3):437-48
   PubMed Web of Science ®Google Scholar
• Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:483-91
   PubMedGoogle Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy : therapeutical vaccines for allergic diseases. A WHO position paper Allergy 1998;102(4pt1):558-62
   Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group; World Health Organization. Allergic Rhinitis and its Impact on Asthma. J Allergy Clin Immunol 2001;108(5 suppl):S146-50
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration With the World Health Organization, GA(2)LEN and AllerGEN). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. World Allergy Organization position paper on sublingual immunotherapy. Allergy 2009;64(Suppl 91):1-59
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: world Allergy Organization position paper 2013 update. World Allergy Organ 2014;7(1):6
   PubMedGoogle Scholar
• Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117(5):1021-35
   PubMed Web of Science ®Google Scholar
• Cox L, Aaronson D, Casale TB, et al. Allergy Immunotherapy Safety :location Matters! J Allergy Clin Immunol Pract. 2013;1(5):455-7
   Google Scholar
• Nelson HS. Sublingual immunotherapy: the U.S. experience. Curr Opin Allergy Clin Immunol 2013;13(6):663-8
   PubMed Web of Science ®Google Scholar
• Nelson HS. Specific immunotherapy with allergen mixes: what is the evidence? Curr Opin Allergy Clin Immunol 2009;9(6):549-53
   PubMed Web of Science ®Google Scholar
• Passalacqua G. The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidence. Curr Opin Allergy Clin Immunol 2014;14(1):20-4
   PubMed Web of Science ®Google Scholar
• Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. J Asthma 2014;51(1):29-33
   PubMed Web of Science ®Google Scholar
• Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103(6):451-9
   Google Scholar
• Baena Cagnani CE, Larenas Linemann D, Sisul C, et al. Allergy training and immunotherapy in Latin American: results of a regional overview. Ann Allergy Asthma Immunol 2013;111(5):415-19
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Baena Cagnani C, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132(1):93-8
   PubMed Web of Science ®Google Scholar
• Larenas Linneman D, Lockey RF, Passalacqua G. Speaking a common language in immunotherapy. WAO grading of systemic reactions. J Allergy Clin Immunol 2010;125(3):569-74
   PubMed Web of Science ®Google Scholar
• Casale T, Canonica GW, Bousquet J, et al. Recommendations for Appropriate Sublingual Immunotherapy (SLIT) Clinical Trials. J Allergy Clin Immunol 2009;124(4):665-70
   PubMed Web of Science ®Google Scholar
• Canonica GW, Baena Cagnani C, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62(3):317-24
   PubMed Web of Science ®Google Scholar
• Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69(7):854-67
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy 2013;43(1):22-8
   PubMed Web of Science ®Google Scholar
• Pajno GB, Caminiti L, Passalacqua G. Changing the route of immunotherapy administration: an 18-year survey in pediatric patients with allergic rhinitis and asthma. Allergy Asthma Proc 2013;34(6):523-6
   PubMed Web of Science ®Google Scholar
• Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO-ARIA-GA2LEN consensus document on molecular-based Allergy diagnostics. World Allergy Organ J 2013;6(1):17
   PubMedGoogle Scholar
• Canonica GW, Passalacqua G. Disease modifying effect and economic implications of Sublingual immunotherapy. J Allergy Clin Immunol 2011;127(1):44-5
   PubMed Web of Science ®Google Scholar
• Soyer OU, Akdis M, Ring J, et al. Mechanisms of peripheral tolerance to allergens. Allergy 2013;68(2):161-70
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133(3):621-31
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Landi M, Pajno GB. Oral immunotherapy for cow’s milk allergy. Curr Opin Allergy Clin Immunol 2012;12(3):271-7
   PubMed Web of Science ®Google Scholar
• Pajno GB, Caminiti L, Crisafulli G, Salzano G. Recent advances in immunotherapy: the active treatment of food allergy on the horizon. Expert Rev Clin Immunol 2012;9(10):891-3
   Web of Science ®Google Scholar
• Kostadinova AI, Willemsen LE, Knippels LM, Garssen J. Immunotherapy-risk/benefit in food allergy. Pediatr Allergy Immunol 2013;24(7):633-44
   PubMed Web of Science ®Google Scholar
• Mansfield LE. Oral immunotherapy for peanut allergy in clinical practice is ready. Allergy Asthma Proc 2013;34:3-205-9
   PubMed Web of Science ®Google Scholar
• Sun J, Hui X, Ying W, et al. Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials. Allergy Asthma Proc 2014;35(2):171-7
   PubMed Web of Science ®Google Scholar
• Kulis M, Burks WA. A Oral immunotherapy for food allergy: clinical and preclinical studies. Adv Drug Deliv Rev 2013;65(6):774-81
   PubMed Web of Science ®Google Scholar
• Fernández-Rivas M, Garrido Fernández S, Nadal JA, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009;64((6)):876-83
   PubMed Web of Science ®Google Scholar
• Enrique E, Malek T, Pineda F, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol 2008;100(3):283-4
   PubMed Web of Science ®Google Scholar
• Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011;127(4):865-72
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129(5):1290-6
   PubMed Web of Science ®Google Scholar
• von Moos S, Kündig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am 2011;31(2):391-406
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129(1):128-35
   PubMed Web of Science ®Google Scholar
• Kumar Y, Bhatia A. Immunopathogenesis of Allergic Disorders: current Concepts Disclosures. Expert Rev Clin Immunol 2013;9(3):211-16
   PubMed Web of Science ®Google Scholar
• Wang J, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Allergy Asthma Immunol Res 2009;1(1):19-29
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012;67(12):1475-82
   PubMed Web of Science ®Google Scholar
• Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18(5):673-83
   PubMed Web of Science ®Google Scholar
• Lambrecht B, Hammad H. Allergens and the airway epithelium response: gateway to allergic sensitization. J Allergy Clin Immunol 2014;134:499-507
   PubMed Web of Science ®Google Scholar
• Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013;14(6):536-42
   PubMed Web of Science ®Google Scholar
• Walker JA, Mckenzie AN. Development and function of group 2 innate lymphoid Cells. Curr Opin Immunol 2013;25(2):148-55
   PubMed Web of Science ®Google Scholar
• Pellerin L, Jenks JA, Bégin P, et al. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res 2014;58(2-3):358-68
   PubMed Web of Science ®Google Scholar
• Lu TX, Hartner J, Lim EJ, et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-γ pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol 2011;187(6):3362-73
   PubMed Web of Science ®Google Scholar
• Mattes J, Collison A, Plank M, et al. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci 2009;106(44):18704-9
   PubMed Web of Science ®Google Scholar
• Dullaers M, De Bruyne R, Ramadani F, et al. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol 2012;129(3):635-45
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454(7203):445-54
   PubMed Web of Science ®Google Scholar
• Deckers J, Branco Madeira F, Hammad H. Innate immune cells in asthma. Trends Immunol 2013;34(11):540-7
   PubMed Web of Science ®Google Scholar
• Shifren A, Witt C, Christie C, Castro M. Mechanisms of Remodeling in Asthmatic Airways. Journal of Allergy 2012;2012:316049
   PubMedGoogle Scholar
• Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol 2007;120(6):1233-44
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127(1 suppl):S1-55
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen Immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 pt 1):558-62
   PubMed Web of Science ®Google Scholar
• The use of standardized allergen extracts. American Academy of Allergy, Asthma and Immunology (AAAAI). J Allergy Clin Immunol 1997;99:583-6
   PubMed Web of Science ®Google Scholar
• Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000;106(1pt 1):41-5
   PubMed Web of Science ®Google Scholar
• Moingeon P. Adjuvants for allergy vaccines. Hum Vaccin Immunother 2012;8(10):1492-8
   PubMed Web of Science ®Google Scholar
• Rosewich M, Lee D, Zielen S. Pollinex Quattro An innovative four injections immunotherapy in allergic rhinitis. Human Vacc Immunother 2013;9(7):1523-31
   PubMed Web of Science ®Google Scholar
• Ito T, Yang M, Wang YH, et al. Plasmocytoid dendritic cells prime IL-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007;204(1):105-15
   PubMed Web of Science ®Google Scholar
• Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Specific immunotherapy and turning off the T cell: how does it work? Ann Allergy Asthma Immunol 2011;107(5):381-92
   PubMed Web of Science ®Google Scholar
• Zhang H, Kong H, Zeng X, et al. Subsets of regulatory T cells and their roles in allergy. J Transl Med 2014;12:125
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33(5):1205-14
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124(3):471-7
   PubMed Web of Science ®Google Scholar
• Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-specific immunotheraphy. Allergy Asthma Immunol Res 2011;3(1):11-20
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis M, Budak F, et al. IL- 10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33(5):1205-14
   PubMed Web of Science ®Google Scholar
• Meiler F, Zumkehr J, Klunker S, et al. In vivo switch to IL- 10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205(12):2887-98
   PubMed Web of Science ®Google Scholar
• Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005;136(3):287-94
   PubMed Web of Science ®Google Scholar
• Chen KW, Blatt K, Thomas WR, et al. Hypollergenic Der p1/Der p2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol 2012;130(2):453-43
   PubMed Web of Science ®Google Scholar
• Marcucci F, Incorvaia C, Sensi L, et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol 2008;21(3):609-13
   PubMed Web of Science ®Google Scholar
• Varney VA, Hamid QA, Gaga M, et al. Influence of grass Pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92(2):644-51
   PubMed Web of Science ®Google Scholar
• Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99(2):254-60
   PubMed Web of Science ®Google Scholar
• Vickery BP, Scurlock AM, Jones SM, Burks AW. Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin Immunol 2011;127(3):576-86
   PubMed Web of Science ®Google Scholar
• Syed A, Garcia MA, Lyu SC, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 2014;133(2):500-10
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puv RM, Weiner JM. Is Allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151(4):969-74
   PubMed Web of Science ®Google Scholar
• Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double- blind, placebo-controlled studies. Clin Ther 2000;22(3):342-50
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341(7):468-75
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma :10-year follow-up on the PAT study. Allergy 2007;62(8):943-8
   PubMed Web of Science ®Google Scholar
• Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitization in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31(9):1392-7
   PubMed Web of Science ®Google Scholar
• Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011;41(9):1177-200
   PubMed Web of Science ®Google Scholar
• Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60(1):4-12
   PubMed Web of Science ®Google Scholar
• Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66(6):740-52
   PubMed Web of Science ®Google Scholar
• Calderon MA, Penagos A, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allerg 2011;41(9):1263-72
   PubMed Web of Science ®Google Scholar
• Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101(2):206-11
   PubMed Web of Science ®Google Scholar
• Novembre E, Galli E, Landi F, et al. Co-seasonal sublingual immunotherapy reduces the development of asthma in children with rhinoconjunctivitis. J Allergy Clin Immunol 2004;114(4):851-7
   PubMed Web of Science ®Google Scholar
• Pajno GB, Passalacqua G, Vita D, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004;59(8):883-7
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Calderon MA, Demoly P, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011;127(1):49-56
   PubMed Web of Science ®Google Scholar
• Senna G, Calderon M, Makatsori M, et al. An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011;11(4):375-80
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115(3):459-65
   PubMed Web of Science ®Google Scholar
• Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113(2):297-302
   PubMed Web of Science ®Google Scholar
• MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. The Journal of Immunology 1997;158(3):1438-45
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64(12):1728-36
   PubMed Web of Science ®Google Scholar
• Khoriaty E, Umetsu DT. Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res 2013;5(1):3-15
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-90
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109(2):274-80
   PubMed Web of Science ®Google Scholar
• Leung DYM, Sampson HA, Yunginger JW, et al. Effect of Anti-IgE Therapy in Patients with Peanut Allergy. N Engl J Med 2003;348(11):986-93
   PubMed Web of Science ®Google Scholar
• Begin P, Dominguez T, Wilson S, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014;10(1):7
   PubMed Web of Science ®Google Scholar
• Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab. Mucosal Immunol 2012;5(3):267-76
   PubMed Web of Science ®Google Scholar
• Gernez Y, Tirouvanziam R, Yu G, et al. Basophil CD203c Levels Are Increased at Baseline and can Be Used to Monitor Omalizumab Treatment in Subjects with Nut Allergy. Int Arch Allergy Immunol 2011;154(4):318-27
   PubMed Web of Science ®Google Scholar
• Corren J. Anti-interleukin-5 antibody therapy in asthma and allergies. Curr Opin Allergy Clin Immunol 2011;11(6):565-70
   PubMed Web of Science ®Google Scholar
• Leckie MJ, Brinke At, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. The Lancet 2007;356(9248):2144-8
   Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108(2):250-7
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. N Engl J Med 2008;358(12):1215-28
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM):a multicentre, double-blind, placebo-controlled trial. The Lancet 2012;380(9842):651-9
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129(2):456-63. e453
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for Poorly Controlled, Eosinophilic Asthma. Am J Respir Crit Care Med 2011;184(10):1125-32
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013;132(5):1086-96. e1085
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60(5):693-6
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. The Lancet 2007;370(9596):1422-31
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. N Engl J Med 2013;368(26):2455-66
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 Receptor in Moderate Atopic Asthma. Am J Respir Crit Care Med 1999;160(6):1816-23
   PubMed Web of Science ®Google Scholar
• Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of amg 317, an il-4rα antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181(8):788-96
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab Treatment in Adults with Asthma. N Engl J Med 2011;365(12):1088-98
   PubMed Web of Science ®Google Scholar
• De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014;133(4):989-96. e984
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. European Respiratory Journal 2013;41(2):330-8
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet L-P, et al. Effects of an Anti-tslp antibody on allergen- induced asthmatic responses. N Engl J Med 2014;370(22):2102-10
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo- controlled, double-blind trial. Allergy 2012;67(12):1572-9
   PubMed Web of Science ®Google Scholar
• Straumann A, Hoesli S, Bussmann C, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68(3):375-85
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 2014;69(9):1223-32
   PubMed Web of Science ®Google Scholar
• Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 2014;44(8):1044-52
   PubMed Web of Science ®Google Scholar
• Busse WW, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clini Immunol 2013;131(2):339-45
   PubMed Web of Science ®Google Scholar
• Snell N, Foster M, Vestbo J. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med 2013;107(11):1722-30
   PubMed Web of Science ®Google Scholar
• Qu C, Srivastava K, Ko J, et al. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up- regulation of interferon-γ. Clin Exp Allergy 2007;37(6):846-55
   PubMed Web of Science ®Google Scholar
• Wang J, Patil SP, Yang N, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 2010;105(1):75-84. e71
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18(5):716-25
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471-84
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed–toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355(14):1445-55
   PubMed Web of Science ®Google Scholar
• Beeh K-M, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013;131(3):866-74
   PubMed Web of Science ®Google Scholar
• Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003- QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41(9):1305-12
   PubMed Web of Science ®Google Scholar
• Kaufman EH, Fryer AD, Jacoby DB. Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs. J Allergy Clin Immunol 2011;127(2):462-9
   PubMed Web of Science ®Google Scholar
• Matthew G, Drake EHK, Allison D. Fryer and David B. Jacoby. The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma. Inflamm Allergy Drug Targets 2012;11(6):484-91
   PubMedGoogle Scholar
• Biffen M, Matsui H, Edwards S, et al. Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity. Br J Pharmacol 2012;166(2):573-86
   PubMed Web of Science ®Google Scholar
• DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32(3):239-47
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56(6):498-505
   PubMed Web of Science ®Google Scholar
• Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol 2014;133(1):121-9. e122
   PubMed Web of Science ®Google Scholar
• Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol 2013;13(3):249-56
   PubMed Web of Science ®Google Scholar